We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+2%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$339M
AUM Growth
+$36.2M
Cap. Flow
+$31.5M
Cap. Flow %
9.29%
Top 10 Hldgs %
40.44%
Holding
118
New
22
Increased
42
Reduced
29
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$9.37M
2
LH icon
Labcorp
LH
+$7.04M
3
JNJ icon
Johnson & Johnson
JNJ
+$6.49M
4
BDX icon
Becton Dickinson
BDX
+$5.83M
5
UHS icon
Universal Health Services
UHS
+$5.72M

Top Sells

Rank Stock Value
1
AMSG
Amsurg Corp
AMSG
+$5.97M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$5.94M
3
HOLX
Hologic
HOLX
+$5.76M
4
CYH icon
Community Health Systems
CYH
+$4.33M
5
CAH icon
Cardinal Health
CAH
+$4.22M

Sector Composition

Rank Sector Weight
1 Healthcare 89.84%
2 Financials 0.85%
3 Technology 0.78%
4 Real Estate 0.25%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LITS
101
Lite Strategy Inc
LITS
$32.8M
– –
-4,772
Closed -$171K
RVTY icon
102
Revvity
RVTY
$12.6B
– –
-73,950
Closed -$3.78M
SGMO
103
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-27,300
Closed -$428K
WAT icon
104
Waters Corp
WAT
$37B
– –
-22,100
Closed -$2.75M
EGRX
105
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-25,500
Closed -$1.07M
MDRX
106
DELISTED
Veradigm Inc. Common Stock
MDRX
– –
-285,550
Closed -$3.42M
NUVA
107
DELISTED
NuVasive, Inc.
NUVA
– –
-46,600
Closed -$2.14M
SRNE
108
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-97,940
Closed -$1.13M
MGLN
109
DELISTED
Magellan Health Services, Inc.
MGLN
– –
-32,920
Closed -$2.33M
HRC
110
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
– –
-48,250
Closed -$2.36M
AMAG
111
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-10,100
Closed -$552K
HZNP
112
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-29,700
Closed -$771K
EVHC
113
DELISTED
Envision Healthcare Holdings Inc
EVHC
– –
-11,927
Closed -$1.37M
PMC
114
DELISTED
PharMerica Corporation
PMC
– –
-11,900
Closed -$335K
TEAR
115
DELISTED
TearLab Corporation
TEAR
– –
-3,089
Closed -$61K
ASPX
116
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
– –
-59,250
Closed -$5.94M
SLXP
117
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-14,300
Closed -$2.47M
WOOF
118
DELISTED
VCA Inc.
WOOF
– –
-6,250
Closed -$343K
1 2 3 4
5

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Endurant Capital Management held 118 positions worth $339M, up 12% from $303M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Endurant Capital Management deployed $31.5M of net new capital in Q2 2015, opening 22 new positions and adding to 42 existing holdings. Its largest new stake was EndoChoice Holdings, Inc.: 328,501 shares worth $5.37M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 88% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Amsurg Corp, an estimated $5.97M trimmed.

  • Endurant Capital Management's largest Q2 2015 buy was EndoChoice Holdings, Inc.: 328,501 shares worth $5.37M.
  • Endurant Capital Management added most to Merck in Q2 2015, an estimated $9.37M increase.
  • Endurant Capital Management's biggest Q2 2015 reduction was Amsurg Corp, cutting an estimated $5.97M.
  • Endurant Capital Management fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $5.94M.
  • Endurant Capital Management's ten largest holdings make up 40% of its $339M portfolio in Q2 2015.
  • Endurant Capital Management opened 22 new positions and closed 25 in Q2 2015.
  • Endurant Capital Management's portfolio value rose 12% quarter-over-quarter to $339M.

Based on Endurant Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.